Implication of CYP24A1 Splicing in Breast Cancer

Author(s): Chimi Scheible, Marc Thill, Sascha Baum, Erich Solomayer, Michael Friedrich

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 14 , Issue 1 , 2014

Become EABM
Become Reviewer
Call for Editor


The expression of CYP27B1 or vitamin D 1α-hydroxylase (1α-OHase) and CYP24A1 in specific tissues may act as the central part between 25-hydroxyvitamin D [25(OH)D] serum levels and the anticancer effects of1α,25-dihydroxyvitamin D [1α,25(OH)2D3],alternative splicing of these enzymes may affect their biological functions. Here, we describe the expression of CYP24A1 and its splicing variants detected in breast cells and tissues.

Manifestation of CYP24A1 mRNA was measured by RT-PCR followed by western blot analysis for protein expression.

In MCF-7 cells, the expression of CYP24A1 protein was reduced by about 57% compared to MCF-10F cells. Western blot analysis revealed a signal band at 56 kDa, with additional bands detected at 42 and 44 kDa.

The expression of CYP24A1 mRNA was reduced by about 58% in breast cancer tissues. We found only one signal in the benign tissues at 56 kDa in western blot, whereas in malignant tissue, an additional band was detected at 40kDa.

Our results suggest that alternative splicing of CYP24A1 may lead to a catalytically dysfunctional enzyme.

Keywords: Vitamin D3, 24-hydroxylase, splicing variants, MCF-7, MCF-10, breast tissue.

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 08 January, 2014
Page: [109 - 114]
Pages: 6
DOI: 10.2174/18715206113139990311

Article Metrics

PDF: 43